Faculty, Staff and Student Publications

Language

English

Publication Date

2-1-2026

Journal

Hemasphere

DOI

10.1002/hem3.70317

PMID

41694734

PMCID

PMC12895360

PubMedCentral® Posted Date

2-12-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Prognosis in therapy‐related acute myeloid leukemia (T‐AML) remains poor, but understanding outcomes with venetoclax (VEN)‐based therapy is relevant. We retrospectively analyzed 317 adult patients with newly diagnosed T‐AML focusing on lower intensity therapy (LIT) VEN‐containing regimens. Patients with an antecedent myeloid disorder before AML diagnosis were excluded. The median age was 69 years (range 21–92); 50% evaluated patients had a complex karyotype, and 40% evaluated patients had a TP53 mutation. Composite complete response rates were higher with LIT + VEN compared to LIT (58% vs. 40%, P = 0.003) but were similar in intensive chemotherapy (IC) + VEN versus IC alone (68% vs. 61%, P = 0.59). Rates of allogeneic hematopoietic stem cell transplantation (HSCT) were higher in VEN‐treated patients: 22% versus 7% in LIT + VEN and LIT, and 64% versus 39% in IC + VEN and IC, respectively. At a median follow‐up of 46.4 months, the median relapse‐free survival (RFS) and overall survival (OS) of the full cohort were 7.2 and 8.4 months, respectively. Among LIT + VEN‐treated patients, the median RFS and OS were 8.0 and 9.0 months, respectively; in patients with ELN2024 favorable risk, the median OS was 25.4 months (1‐year OS rate of 62%), compared to 9.4 months in the intermediate (FLT3‐ITD and/or RAS mutated) and 4.8 months in the adverse risk (TP53 mutated) group. Patients with NPM1 and/or IDH mutations had 2‐year OS over 60%. On multivariate analysis in LIT + VEN‐treated patients, HSCT and NPM1/IDH2 mutations were favorable, while TP53/RAS mutations were associated with inferior survival. VEN‐based therapy improves outcomes in patients with T‐AML, especially in those with VEN‐sensitizing genomics and receiving an HSCT.

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.